Laura Kay Buell, MD | |
619 19th St S, Hospitalist Service P915, Birmingham, AL 35249-1900 | |
(205) 975-0512 | |
Not Available |
Full Name | Laura Kay Buell |
---|---|
Gender | Female |
Speciality | Hospitalist |
Experience | 13 Years |
Location | 619 19th St S, Birmingham, Alabama |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275823437 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 31813 (Alabama) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Alabama Hospital | Birmingham, AL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best type 1 diabetes commercial opportunities.
Severely obese patients with chronic kidney disease (CKD) saw significant improvements in kidney function within one year of bariatric surgery, according to a new study presented here at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).
AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
Accidental injuries are among the leading causes of morbidity and mortality in the United States. The Centers for Disease Control and Prevention estimated that unintentional injuries accounted for 5 percent of all deaths in 2011 and 28 million emergency room visits in 2013.
Making the most of the low light in the muddy rivers where it swims, the elephant nose fish survives by being able to spot predators amongst the muck with a uniquely shaped retina, the part of the eye that captures light. In a new study, researchers looked to the fish's retinal structure to inform the design of a contact lens that can adjust its focus.
› Verified 7 days ago
Entity Name | University Of Alabama Health Services Foundation, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best type 1 diabetes commercial opportunities.
Severely obese patients with chronic kidney disease (CKD) saw significant improvements in kidney function within one year of bariatric surgery, according to a new study presented here at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).
AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
Accidental injuries are among the leading causes of morbidity and mortality in the United States. The Centers for Disease Control and Prevention estimated that unintentional injuries accounted for 5 percent of all deaths in 2011 and 28 million emergency room visits in 2013.
Making the most of the low light in the muddy rivers where it swims, the elephant nose fish survives by being able to spot predators amongst the muck with a uniquely shaped retina, the part of the eye that captures light. In a new study, researchers looked to the fish's retinal structure to inform the design of a contact lens that can adjust its focus.
› Verified 7 days ago
Entity Name | University Of Alabama At Birmingham |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1184738478 PECOS PAC ID: 3779487970 Enrollment ID: O20031120000323 |
News Archive
ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best type 1 diabetes commercial opportunities.
Severely obese patients with chronic kidney disease (CKD) saw significant improvements in kidney function within one year of bariatric surgery, according to a new study presented here at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).
AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
Accidental injuries are among the leading causes of morbidity and mortality in the United States. The Centers for Disease Control and Prevention estimated that unintentional injuries accounted for 5 percent of all deaths in 2011 and 28 million emergency room visits in 2013.
Making the most of the low light in the muddy rivers where it swims, the elephant nose fish survives by being able to spot predators amongst the muck with a uniquely shaped retina, the part of the eye that captures light. In a new study, researchers looked to the fish's retinal structure to inform the design of a contact lens that can adjust its focus.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Laura Kay Buell, MD 619 19th St S, Hospitalist Service P915, Birmingham, AL 35249-1900 Ph: (205) 975-0512 | Laura Kay Buell, MD 619 19th St S, Hospitalist Service P915, Birmingham, AL 35249-1900 Ph: (205) 975-0512 |
News Archive
ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best type 1 diabetes commercial opportunities.
Severely obese patients with chronic kidney disease (CKD) saw significant improvements in kidney function within one year of bariatric surgery, according to a new study presented here at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).
AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
Accidental injuries are among the leading causes of morbidity and mortality in the United States. The Centers for Disease Control and Prevention estimated that unintentional injuries accounted for 5 percent of all deaths in 2011 and 28 million emergency room visits in 2013.
Making the most of the low light in the muddy rivers where it swims, the elephant nose fish survives by being able to spot predators amongst the muck with a uniquely shaped retina, the part of the eye that captures light. In a new study, researchers looked to the fish's retinal structure to inform the design of a contact lens that can adjust its focus.
› Verified 7 days ago
Carlos Aristizabal, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35233 Phone: 205-934-4011 | |
Ronnie Mathews, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Mark Cromer, Hospitalist Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-9999 | |
Hugh Davidson Reeves, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-9666 | |
Laura Nye, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Kierstin Kennedy, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Patricia Aiken, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 |